XNAS · RNAZ
-1.74% · -$0.0300 · Vol 30.9K
Market closed · last close 4:00 PM ET · price as of 19:30:04 ET
TransCode Therapeutics, Inc. Common Stock

TransCode Therapeutics, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$1.69
Card
Relationship Map

Follow $RNAZ

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $RNAZ by email

Veridion Score

BETALOW CONF · 4 of 6 factors measuredMethodology
Valuation absence reason unknown · Sentiment absence reason unknown
RNAZ
TransCode Therapeutics, Inc. Common Stock
Sat Sep 19 · market closed · Markets closed · resumes Mon 9:30 ET
Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

34/ 100
Veridion Score
Lower range · LOW confidence · 4 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4 of 6 factors measured · Sat Sep 19 · market closed · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is RNAZ moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading RNAZ catalysts
About TransCode Therapeutics, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
2021
Employees
12
Country
US

TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.00
Day high
$2.00
Day low
$1.65
Previous close
$1.72
52W high
$15.23
-88.90% from high
52W low
$1.60
1% of range
Market cap
$27.9M
EPS
$-39.4000
Beta
1.21
Shares out
16.9M
Volume
30.9K
0.46× rel vol
Avg volume
67.5K
VWAP
$1.72
Price history computed in-house
1W
0.00%
1M
-43.10%
3M
-64.04%
1Y
-85.54%
YTD
-75.26%
SMA 50 $4.17 · below
SMA 200 $7.11 · below
52W position 1%

RNAZ overview

Veridion Score
34
Registered · 2026-09-18
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around RNAZ.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading RNAZ Form 4 filings
Public disclosures

Congress activity in RNAZ

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for RNAZ in the cached public ledger.

Federal contracts

RNAZ contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for RNAZ in this window.
Lobbying spend

RNAZ lobbying filings, year to date.

Registered lobbying filings matched to TransCode Therapeutics, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for RNAZ in this window.
Loading news for RNAZ
Analyst ratings
Sovereign unlock shows live analyst consensus for RNAZ.
Options
Sovereign unlock shows live options positioning for RNAZ.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.